68 related articles for article (PubMed ID: 26399788)
1. GPR119: a promising target for nonalcoholic fatty liver disease.
Yang JW; Kim HS; Im JH; Kim JW; Jun DW; Lim SC; Lee K; Choi JM; Kim SK; Kang KW
FASEB J; 2016 Jan; 30(1):324-35. PubMed ID: 26399788
[TBL] [Abstract][Full Text] [Related]
2. Involvement of G-Protein-Coupled Receptor 40 in the Inhibitory Effects of Docosahexaenoic Acid on SREBP1-Mediated Lipogenic Enzyme Expression in Primary Hepatocytes.
On S; Kim HY; Kim HS; Park J; Kang KW
Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31142011
[TBL] [Abstract][Full Text] [Related]
3. The PKA-SREBP1c Pathway Plays a Key Role in the Protective Effects of Lactobacillus johnsonii JNU3402 Against Diet-Induced Fatty Liver in Mice.
Hong E; Kang H; Yang G; Oh S; Kim E
Mol Nutr Food Res; 2023 Oct; 67(20):e2200496. PubMed ID: 37650271
[TBL] [Abstract][Full Text] [Related]
4. Si-Ni-San inhibits hepatic Fasn expression and lipid accumulation in MAFLD mice through AMPK/p300/SREBP-1c axis.
Lan T; Geng XJ; Zhang SJ; Zeng XX; Ying JJ; Xu Y; Liu SY; Li P; Tong YH; Wang W; Mao ZJ; Wang SW
Phytomedicine; 2024 Jan; 123():155209. PubMed ID: 37984123
[TBL] [Abstract][Full Text] [Related]
5. Sesamin ameliorates lipotoxicity and lipid accumulation through the activation of the estrogen receptor alpha signaling pathway.
Pham TH; Lee GH; Jin SW; Lee SY; Han EH; Kim ND; Choi CY; Jeong GS; Ki Lee S; Kim HS; Jeong HG
Biochem Pharmacol; 2023 Oct; 216():115768. PubMed ID: 37652106
[TBL] [Abstract][Full Text] [Related]
6. The GPR40 novel agonist SZZ15-11 improves non-alcoholic fatty liver disease by activating the AMPK pathway and restores metabolic homeostasis in diet-induced obese mice.
Lei L; Gao X; Zhai J; Liu S; Liu Q; Li C; Cao H; Feng C; Chen L; Lei L; Pan X; Li P; Liu Z; Huan Y; Shen Z
Diabetes Obes Metab; 2024 Jun; 26(6):2257-2266. PubMed ID: 38497233
[TBL] [Abstract][Full Text] [Related]
7. O-1602 Promotes Hepatic Steatosis through GPR55 and PI3 Kinase/Akt/SREBP-1c Signaling in Mice.
Kang S; Lee AY; Park SY; Liu KH; Im DS
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33803038
[TBL] [Abstract][Full Text] [Related]
8. Sesamin ameliorates nonalcoholic hepatic steatosis by inhibiting CD36-mediated hepatocyte lipid accumulation in vitro and in vivo.
Bai YP; Zhang T; Hu ZY; Zhang Y; Wang DG; Zhou MY; Zhang Y; Zhang F; Kong X
Biochem Pharmacol; 2024 Jun; 224():116240. PubMed ID: 38679210
[TBL] [Abstract][Full Text] [Related]
9. Hepatic G Protein-Coupled Receptor 180 Deficiency Ameliorates High Fat Diet-Induced Lipid Accumulation via the Gi-PKA-SREBP Pathway.
Zhang Y; Zhu Z; Sun L; Yin W; Liang Y; Chen H; Bi Y; Zhai W; Yin Y; Zhang W
Nutrients; 2023 Apr; 15(8):. PubMed ID: 37111058
[TBL] [Abstract][Full Text] [Related]
10. N-3 Polyunsaturated Fatty Acids Protect against Alcoholic Liver Steatosis by Activating FFA4 in Kupffer Cells.
Kang S; Koh JM; Im DS
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791514
[TBL] [Abstract][Full Text] [Related]
11. DNMT3B Alleviates Liver Steatosis Induced by Chronic Low-grade LPS via Inhibiting CIDEA Expression.
Li Q; Wang W; Duan F; Wang Y; Chen S; Shi K; Xia Y; Li X; Gao Y; Liu G
Cell Mol Gastroenterol Hepatol; 2024; 17(1):59-77. PubMed ID: 37703946
[TBL] [Abstract][Full Text] [Related]
12. Hepatic glycogenesis antagonizes lipogenesis by blocking S1P via UDPG.
Chen J; Zhou Y; Liu Z; Lu Y; Jiang Y; Cao K; Zhou N; Wang D; Zhang C; Zhou N; Shi K; Zhang L; Zhou L; Wang Z; Zhang H; Tang K; Ma J; Lv J; Huang B
Science; 2024 Feb; 383(6684):eadi3332. PubMed ID: 38359126
[TBL] [Abstract][Full Text] [Related]
13. Effect of FTY720P on lipid accumulation in HEPG2 cells.
Rida R; Kreydiyyeh S
Sci Rep; 2023 Nov; 13(1):19716. PubMed ID: 37953311
[TBL] [Abstract][Full Text] [Related]
14. GPR119 activation by DA-1241 alleviates hepatic and systemic inflammation in MASH mice through inhibition of NFκB signaling.
Lee SH; Park H; Yang EK; Lee BR; Jung IH; Kim TH; Goo MJ; Chae Y; Kim MK
Biomed Pharmacother; 2023 Oct; 166():115345. PubMed ID: 37657264
[TBL] [Abstract][Full Text] [Related]
15. MBX-102/JNJ39659100, a novel non-TZD selective partial PPAR-γ agonist lowers triglyceride independently of PPAR-α activation.
Chandalia A; Clarke HJ; Clemens LE; Pandey B; Vicena V; Lee P; Lavan BE; Gregoire FM
PPAR Res; 2009; 2009():706852. PubMed ID: 19404482
[TBL] [Abstract][Full Text] [Related]
16. Structure of human GPR119-G
Li R; Qian Y; Wang J; Han Z; Ye S; Wu S; Qiao A
Front Pharmacol; 2024; 15():1310231. PubMed ID: 38288442
[TBL] [Abstract][Full Text] [Related]
17. G Protein-Coupled Receptor 119 (GPR119) Agonists for the Treatment of Diabetes: Recent Progress and Prevailing Challenges.
Ritter K; Buning C; Halland N; Pöverlein C; Schwink L
J Med Chem; 2016 Apr; 59(8):3579-92. PubMed ID: 26512410
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic application of GPR119 ligands in metabolic disorders.
Yang JW; Kim HS; Choi YW; Kim YM; Kang KW
Diabetes Obes Metab; 2018 Feb; 20(2):257-269. PubMed ID: 28722242
[TBL] [Abstract][Full Text] [Related]
19. G protein-coupled receptors: signalling and regulation by lipid agonists for improved glucose homoeostasis.
Moran BM; Flatt PR; McKillop AM
Acta Diabetol; 2016 Apr; 53(2):177-88. PubMed ID: 26739335
[TBL] [Abstract][Full Text] [Related]
20. A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer.
Asgharpour A; Cazanave SC; Pacana T; Seneshaw M; Vincent R; Banini BA; Kumar DP; Daita K; Min HK; Mirshahi F; Bedossa P; Sun X; Hoshida Y; Koduru SV; Contaifer D; Warncke UO; Wijesinghe DS; Sanyal AJ
J Hepatol; 2016 Sep; 65(3):579-88. PubMed ID: 27261415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
